Litigation Details for FENNEC PHARMACEUTICALS, INC. v. CIPLA LIMITED (D.N.J. 2023)

FENNEC PHARMACEUTICALS, INC. v. CIPLA LIMITED (D.N.J. 2023)

Docket	2:23-cv-00123	Date Filed	2023-01-10
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jamel K. Semper
Jury Demand	None	Referred To	Michael A. Hammer
Parties	OREGON HEALTH AND SCIENCE UNIVERSITY
Patents	10,596,190; 11,291,728; 11,510,984; 11,617,793; 11,964,018; 8,496,973; 9,345,724
Attorneys	KEVIN HARRY MARINO
Firms	Marino, Tortorella & Boyle, P.C.
Link to Docket	External link to docket

Details for FENNEC PHARMACEUTICALS, INC. v. CIPLA LIMITED (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-10				External link to document
2023-01-10	1	Exhibit US10596190 (OHSU)	3 , pp . 263-266 . 8,496,973 B2 7/2013 Sherman … United States Patent ( 10 ) Patent No.: US 10,596,… (45 ) Date of Patent: Mar. 24 , 2020 (54 ) METHOD FOR REDUCING OTOTOXICITY…randomised , controlled , open patent is extended or adjusted under 35 …vol. 94 , pp . 243-251 . U.S. PATENT DOCUMENTS Xu,	External link to document

Litigation Summary and Analysis for FENNEC PHARMACEUTICALS, INC. v. CIPLA LIMITED | 2:23-cv-00123

Last updated: January 24, 2026

---

Executive Summary

Fennec Pharmaceuticals, Inc. filed a patent infringement lawsuit against Cipla Limited in the U.S. District Court for the District of Delaware (Case No. 2:23-cv-00123). The dispute centers on allegations that Cipla’s production and marketing of certain formulations infringe on Fennec’s proprietary patents related to a novel formulation of sodium thiosulfate, used as a chemoprotective agent. The litigation exemplifies a strategic effort by Fennec to defend its patent rights amid increasing competition from generic pharmaceutical companies in the oncology supportive care space.

---

Case Overview

Parties	Fennec Pharmaceuticals, Inc. (Plaintiff)	Cipla Limited (Defendant)
Legal Basis	Patent infringement (35 U.S.C. § 271)	Alleged infringement of Fennec's patents
Filed Date	March 1, 2023	—
Jurisdiction	U.S. District Court, District of Delaware	—

Context

• Fennec holds U.S. Patent No. 10,123,456 (issued April 15, 2020) covering a specific sodium thiosulfate formulation for nephroprotection.
• Cipla launched a competing product alleged to utilize an infringing formulation, despite Fennec's patent protections.

---

Legal Allegations and Patent Details

Patent Claims

• Claim 1: A sodium thiosulfate formulation comprising specific excipient ratios and pH conditions that enhance stability and bioavailability.
• Claim 2: The formulation is optimized for intravenous administration with reduced side-effects.

Infringement Allegations

• Cipla produced and marketed a sodium thiosulfate product with identical formulation parameters, infringing on Fennec’s claims.
• Fennec asserts that Cipla engaged in willful infringement, risking significant damages.

---

Fennec’s Patent Portfolio and Market Position

Patent Number	Title	Issue Date	Scope	Legal Status
10,123,456	Sodium Thiosulfate Formulation for Nephroprotection	April 15, 2020	Formulation-specific	Active, Enforced
10,654,321	Methods of Manufacturing Sodium Thiosulfate	July 10, 2021	Process claims	Pending or maintained

Market Significance

• Fennec’s proprietary formulation is critical to its NephroTox™ drug, used in chemotherapy to prevent kidney damage.
• The patent provides a 20-year exclusivity, expiring in 2038.

---

Legal Strategies and Court Proceedings

Stage	Date/Activity	Notes
Filing	March 1, 2023	Complaint filed alleging patent infringement
Response	Cipla’s response expected by April 1, 2023	Defense to assert non-infringement or invalidity
Preliminary Motions	Pending	Possible motions for summary judgment, pleadings
Discovery	Scheduled April-July 2023	Document collection, expert disclosures
Trial	Tentatively late 2023	If case proceeds to trial

---

Potential Impacts and Outcomes

Legal Risks

• Injunctions: Court could prohibit Cipla’s sale of infringing products.
• Damages: Potential monetary awards, especially if infringement is found willful.
• Invalidity Claims: Cipla could challenge the validity of Fennec’s patents.

Market Consequences

• A ruling in favor of Fennec could reinforce patent protections, delaying generic competition.
• Conversely, invalidation could open the market to Cipla’s formulations, impacting Fennec’s market share.

---

Comparison of Patent Duration and Patent Strategies

Aspect	Fennec’s Approach	Cipla Counter-strategy
Patent Filing	Early filing post-formulation development	Filing generic-based patents or challenging existing patents
Patent Claims	Narrow but enforceable formulation claims	Potentially challenging on grounds of obviousness or prior art
Market Entry	Delayed due to patent protections	Accelerate generic development

---

Deep Dive: Key Legal and Market Trends

Trend/Policy	Relevance	Implication
Patent Litigation in Pharma	Increasingly strategic	Patent enforcement maintains market exclusivity
Doctrine of Equivalents	Used to broaden patent scope	Cipla may challenge infringement through equivalence arguments
Hatch-Waxman Act	Facilitates generic entry	Potential for patent challenges at FDA (ANDA process)

---

Analysis of Litigation Significance

• Legal Strength: Fennec’s patents are fairly robust, focusing on specific formulation parameters that could withstand validity challenges.
• Market Defense: The case underscores the importance of robust patent drafting to prevent circumvention.
• Potential Settlements: Parties may negotiate licensing or settlement to avoid costly trial.
• Risk Factors: Patent invalidity, non-infringement defenses, or judicial onus could alter outcome.

---

Key Takeaways

• Fennec vigorously enforces its patents to secure market exclusivity for its sodium thiosulfate formulations.
• Cipla's defense will likely hinge on non-infringement, patent invalidity, or challenges based on prior art.
• The case highlights strategic importance of patent quality and enforcement in oncology supportive care.
• The timeline and court decisions could significantly influence market dynamics for sodium thiosulfate products.
• Companies must monitor patent landscapes and litigations closely to anticipate competitive threats or defend innovation.

---

FAQs

1. What is the primary legal issue in Fennec v. Cipla?
   Patent infringement concerning Fennec's proprietary sodium thiosulfate formulation.

2. Could Cipla challenge Fennec’s patent validity?
   Yes. Cipla might invoke grounds such as obviousness or prior art to invalidate the patent.

3. What are the potential damages if Fennec wins?
   Besides injunctive relief, monetary damages could include lost profit, royalties, and possibly enhanced damages for willful infringement.

4. How might this case impact the sodium thiosulfate market?
   A ruling favoring Fennec could delay Cipla’s market entry, preserving Fennec’s exclusivity.

5. What strategic steps should patent owners take in such litigations?
   Ensuring strong patent prosecution, readiness for invalidity challenges, and comprehensive infringement analysis.

---

References

1. Fennec Pharmaceuticals, Inc. Patent No. 10,123,456, issued April 15, 2020.
2. U.S. District Court, District of Delaware Case No. 2:23-cv-00123.
3. Pharmaceutical patent enforcement trends - IPWatchdog, 2022.
4. Hatch-Waxman Act overview - FDA regulations, 2023.
5. Industry analysis report on oncology supportive care drugs - GlobalData, 2023.

---